CSIMarket Company Name, Ticker, Customers, else..
 
Cg Oncology Inc   (NASDAQ: CGON)
 
Price: $73.4000 $-1.27 -1.701%
Day's High: $74.5999984741211 Week Perf: -3.24 %
Day's Low: $ 72.25 30 Day Perf: -2.26 %
Volume (M): 550,205 52 Wk High: $ 80.97
Volume (M$): $ 0 52 Wk Avg: $56.76
Open: $74.60 52 Wk Low: $32.50



 Market Capitalization (Millions $) 6,474
 Shares Outstanding (Millions) 88
 Employees 142
 Revenues (TTM) (Millions $) 6
 Net Income (TTM) (Millions $) -224
 Cash Flow (TTM) (Millions $) 19
 Capital Exp. (TTM) (Millions $) 1

Business Description


The company develops and commercializes therapeutic products, including cretostimogene, for the treatment of high-risk and intermediate-risk non-muscle invasive bladder cancer (NMIBC). It conducts clinical trials and preclinical studies to assess the safety and efficacy of its product candidates and intends to pursue regulatory approvals and commercialization upon approval.


   Company Address: 3000 Pegasus Park Drive Dallas 75247 TX
   Company Phone Number: 409-3700   Stock Exchange / Ticker: NASDAQ CGON


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
IBRX        4.28% 
TARA        0.78% 
URGN        1.68% 
• View Complete Report
   



Clinical Study

CG Oncologys PIVOT-006 Enrollment Completion A Landmark Moment in Addressing Unmet Needs in Advanced Treatments for ...

Published Wed, Sep 3 2025 12:45 PM UTC

CG Oncology Completes Enrollment in PIVOT-006: A Landmark Step in Addressing Unmet Needs in Intermediate-Risk Non-Muscle Invasive Bladder Cancer In a significant advancement for urologic oncology, CG Oncology has announced the completion of patient enrollment for its pivotal clinical trial, PIVOT-006, which is set against the backdrop of a high unmet need for effective treat...
Clinical Study

Evaluating Cretostimogene Grenadenorepvec Monotherapy Promise and Market Performance in BCG-Unresponsive Non-Muscle I...

Published Thu, Dec 5 2024 12:00 PM UTC

: In recent developments within oncological therapies, particularly in the treatment of non-muscle invasive bladder cancer (NMIBC), Cretostimogene Grenadenorepvec, an innovative oncolytic immunotherapy, marks a significant milestone. This article critically examines the data supporting its efficacy in delivering sustained and durable complete responses in high-risk, Bacillus...
Clinical Study

Novel Immunotherapy Combination Shows Promise in Treating Non-Muscle Invasive Bladder Cancer

Published Thu, Jun 6 2024 4:14 PM UTC

In a recent publication in the prestigious Nature Medicine journal, CG Oncology has announced the final results from its CORE-001 study involving the use of Cretostimogene Grenadenorepvec (CG0070) in combination with Pembrolizumab as a potential treatment for Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC). This groundbreaking study sh...
Product Service News

CG Oncology Announces Promising Phase 2 Results for Cretostimogene Grenadenorepvec and Pembrolizumab Combination in Treating High-Risk NMIBC'

Published Fri, May 24 2024 12:00 PM UTC

CG Oncology, a clinical-stage biopharmaceutical company, has announced the final positive results from their Phase 2 CORE-001 study evaluating the combination therapy of cretostimogene grenadenorepvec and pembrolizumab in patients with BCG-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC). The findings are set to be presented at the American Society of Clinic...
Announcement

Revolutionary Breakthrough: Cretostimogene Monotherapy Delivers Unprecedented 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Published Fri, May 3 2024 3:23 PM UTC

Cretostimogene Monotherapy Shows Remarkable 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder CancerBladder cancer is a significant health concern globally, with non-muscle invasive bladder cancer (NMIBC) accounting for nearly three-quarters of all cases. While Bacillus Calmette-Guérin (BCG) immunotherapy has long been the standard trea...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 1,039.48
Price to Sales (Expected) -
Price to Book 6.29
PEG (TTM) -

Financial Strength Current
Quick Ratio 21.77
Working Capital Ratio 22.22
Leverage Ratio (MRQ) 0.05
Total Debt to Equity 0
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -2.71 $
Revenues (TTM) 0.07 $
Cash Flow (TTM) 0.22 $
Cash 11.66 $
Book Value 11.67 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 43,859
Net Income per Employee (TTM) -1,580,106
Receivable Turnover Ratio (TTM) 8.61
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.01

Profitability Ratios Current
Gross Margin (MRQ) 0 %
Operating Margin (MRQ) -7467.68 %
Net Margin (MRQ) -6832.84 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Cg Oncology Inc's Segments
Commercial and Development Revenue    191.53 % of total Revenue
License and Collaboration Revenue    2.07 % of total Revenue
Member    193.6 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.